Background: In a phase III study of P+Cis versus Cis, MPM pts demonstrated a significant survival benefit (12.1 mo vs 9.3 mo median survival; 50.3% vs 38.0% 1-yr survival) and clinical benefit in ...

Fresenius Kabi PEMEtrexed for Injection, USP is an affordable treatment option for adult patients with non-squamous non-small cell lung cancer and malignant pleural mesothelioma.

Overall survival for cisplatin/pemetrexed was noninferior to cisplatin/gemcitabine (median survival, 10.3 v 10.3 months, respectively; HR = 0.94; 95% CI, 0.84 to 1.05). Overall survival was ...

Interim results from the FLAURA2 study showed that investigator-assessed median progression-free survival (PFS) improved by 8.8 months with osimertinib plus pemetrexed and platinum chemotherapy ...

Leukopenia may be seen in sepsis as one of the systemic inflammatory response syndrome (SIRS) criteria, ie, white blood cell count below 4000, and may portend a poor prognosis. But severe ...

The Food and Drug Administration (FDA) has approved Pemrydi RTU ® (pemetrexed injection), a ready-to-use (RTU) presentation of pemetrexed. The application was approved through the FDA’s 505 (b ...

Pembrolizumab's new MPM approval was based on the KEYNOTE-483 trial, which randomized 440 patients to receive either pembrolizumab for ≤ 2 years in combination with pemetrexed and platinum-based ...